This parallel, randomized clinical trial was conducted at the Interventional Radiology Department of Al-Zahra Hospital in Isfahan, Iran. Ethics approval was obtained from the Ethics Committee at the Isfahan University of Medical Sciences (code: IR.MUI.MED.REC.1397.224) and registered with the Iranian Registry of Clinical Trials (code: IRCT20191204045600N1).
Study participants included patients who had been admitted to Al-Zahra Hospital between March and October 2019, and for whom the attending physician ordered elective thoracentesis or abdominocentesis. Elective procedures were ordered on diagnostic, curative, or palliative grounds. Patients were included in the study if they were: over 18 years of age, cognitively alert, not pregnant or breastfeeding, without a history of allergies to amides, without dermatologic conditions at procedure cite, did not have G6PD, and did not currently use systemic analgesic medications. Overall, 36 patients were included in the thoracentesis group and 33 patients in the abdominocentesis group. Using random allocation software, patients were randomly coded and divided into two groups by those codes, one group received IL (N = 35), and another received LPC (N = 34).
After explaining the procedures, hazards, and alternatives to the patients, they were free to enter our study. Written informed consent was obtained from all study participants. In addition, participants were told that they were free to withdraw their consent at any time point, and they could ask for more anesthetic if required.
Both thoracentesis and abdominocentesis ultrasound-guided procedures can minimize human errors. The best point for aspiration was determined using ultrasound imaging, which allowed medical staff to mark the point of aspiration. Next, the patients in the IL group received 5cc of lidocaine 2% (100 mg) with a 25-gauge needle, 5 minutes prior to the procedure (
16). Infiltrative lidocaine was first injected subcutaneously and then deeper close to the parietal pleura in the thoracentesis procedure (
3), or close to the peritoneum in the abdominocentesis procedure (
2). The LPC group received 2.5 g of lidocaine-prilocaine cream. The cream that was used contained 2.5 g of lidocaine and 2.5 g of prilocaine per 100 g; it was labeled Xayla-p and made by Tehranchemie.CO. Then, 2.5 g of this cream translates to approximately a 9.5 cm strip of cream. That exact amount of cream was used to cover a 20 - 25 cm
2 area around the spot marked by medical staff. Eventually, this area was covered with dressing plaster. After 30 minutes, the dressing plaster was removed, and any remaining cream was removed with the help of gauze. After this, the thoracentesis or abdominocentesis procedures started. In order to avoid systemic side effects associated with LPC, the following precautions were taken: not using an excessive amount of cream, only by using it in a determined area (20 - 25 cm
2) within a short period of time, as well as not including patients who are under 18 years of age, pregnant, G6PD or those that have dermatologic disease or inflammation at the site of the procedure. Previous studies have shown the possibility of increased systemic side effects if mentioned precautions are not taken into consideration (
17-
19). All thoracentesis and abdominocentesis were both conducted in sterile conditions by the same radiologist. As is standard procedure, a 16 -gauge peripheral venous catheter was used in both procedures.
Immediately after the completion of the procedure, the catheter was removed, and the area was covered with sterile gauze and tape. In addition, directly after the procedure, patients were asked for their overall pain perception using a 0 - 10 numeric rating scale. Next, patients were asked their level of satisfaction using a 0 – 4 -point scale. Patients were asked to express their satisfaction by choosing between: totally satisfied (4), satisfied (3), indifferent (2), dissatisfied (1), or totally dissatisfied (0).
3.1. Statistical Analysis
Data were analyzed using SPSS software, version 23. We used independent t-test, chi-square test, and univariate analysis of variance (ANOVA) due to the normal distribution of data shown by the Kolmogorov-Smirnov test. The significance threshold was set at 0.05 for all analyses. The data were blinded before delivery to the analyzer.